NEW YORK (GenomeWeb) – StemCyte will offer two genetic testing services from Fulgent Genetics as part of a partnership announced today.
Under the terms of the deal, StemCyte, a regenerative therapeutics company, will offer Beacon Expanded Carrier Screening and Newborn Genetic Analysis. Beacon Expanded Carrier Screening is used to identify potential reproductive risks for current or future pregnancies, while Newborn Genetic Analysis is for identifying genetic risks in parents but is performed for newborns. It analyzes 255 genes and assesses more than 200 disorders and identifies DNA changes that may cause severe or life-altering symptoms in infants.
Financial and other terms of the deal were not disclosed.
Based in Temple City, California, Fulgent operates a CLIA-certified and CAP-accredited molecular diagnostics lab in Los Angeles. Among the services it provides are full-gene sequencing with deletion/duplication analysis in single-gene tests; testing on pre-established, multigene, disease-specific panels; and testing on customized panels tailored to meet specific clinical needs.